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ABSTRACT
Background: Non-small-cell lung cancer (NSCLC) patients with activating 
epidermal growth factor receptor (EGFR) mutations may exhibit primary resistance 
to EGFR tyrosine kinase inhibitor (TKI). We aimed to examine genomic alterations 
associated with de novo resistance to gefitinib in a prospective study of NSCLC 
patients.
Methods: One-hundred and fifty two patients with activating EGFR mutations 
were included in this study and 136 patients’ tumor sample were available for targeted 
sequencing of genomic alterations in 22 genes using the Colon and Lung Cancer panel 
(Ampliseq, Life Technologies).
Results: All 132 patients with EGFR mutation were treated with gefitinib for their 
treatment of advanced NSCLC. Twenty patients showed primary resistance to EGFR 
TKI, and were classified as non-responders. A total of 543 somatic single-nucleotide 
variants (498 missense, 13 nonsense) and 32 frameshift insertions/deletions, with 
a median of 3 mutations per sample. TP53 was most commonly mutated (47%) 
and mutations in SMAD4 was also common (19%), as well as DDR2 (16%), PIK3CA 
(15%), STK11 (14%), and BRAF (7%). Genomic mutations in the PI3K/Akt/mTOR 
pathway were commonly found in non-responders (45%) compared to responders 
(27%), and they had significantly shorter progression-free survival and overall 
survival compared to patients without mutations (2.1 vs. 12.8 months, P=0.04, 15.7 
vs. not reached, P<0.001). FGFR 1-3 alterations, KRAS mutations and TP53 mutations 
were more commonly detected in non-responders compared to responders.
Conclusion: Genomic mutations in the PI3K/Akt/mTOR pathway were commonly 
identified in non-responders and may confer resistance to EGFR TKI. Screening lung 
adenocarcinoma patients with clinical cancer gene test may aid in selecting out those 
who show primary resistance to EGFR TKI (NCT01697163).
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INTRODUCTION
Lung cancer is the leading cause of cancer deaths 
worldwide [1]. Adenocarcinoma, which consists of more 
than 50% of non-small-cell lung cancer (NSCLC), is 
the most frequent type. Recent efforts to characterize 
molecular subclassifications of NSCLC have provided 
a marked benefit to patients whose tumors harbor 
specific genetic alterations [2-4], and the three major 
driver oncogenic mutations are epidermal growth factor 
receptor (EGFR) mutation, KRAS mutation, and anaplastic 
lymphoma kinase (ALK) rearrangement.
EGFR activating mutations are the most important 
predictive markers of response to EGFR tyrosine kinase 
inhibitor (TKI) treatment [5]. Despite the demonstrated 
benefits of EGFR TKIs, not all patients respond to treatment. 
Approximately 30% of patients with EGFR activating 
mutations do not show objective responses to EGFR TKI 
[6]. Intrinsic, de novo or primary resistance is defined as the 
failure to respond to EGFR-targeted therapies and little is 
known about the mechanisms of primary resistance. On the 
contrary, acquired resistance occurs in patients who initially 
benefited from EGFR-targeted therapies and the underlying 
mechanisms of acquired resistance include EGFR T790M 
mutation, activation of bypass signaling (such as MET 
amplification, HER2 upregulation or KRAS activation), 
and histologic transformation to small cell lung cancer or 
epithelial-mesenchymal transition [7].
Recent studies have revealed that both somatic 
mutations and germline polymorphisms may result in 
primary resistance to EGFR TKI. For example, mutations 
in phosphoinositide-3-kinase catalytic alpha (PIK3CA), the 
p110α catalytic subunit of phosphatidylinositol-3-kinase, 
are found in approximately 4% of NSCLC patients [8] and 
result in resistance to EGFR TKI. Loss of phosphatase and 
tensin homolog (PTEN) and de novo MET amplification 
could also be associated with resistance [9, 10]. In addition, 
germline polymorphisms of BIM, a pro-apoptotic protein, 
which result in BIM deletion may confer primary resistance 
[11]. SRC and MAP kinase pathways may also act as 
bypass pathways which confer resistance to EGFR TKIs 
[12]. However, other mechanisms of primary resistance 
remain largely unknown.
With the advancement of next-generation sequencing 
(NGS), it is now possible to identify oncogenic alterations 
that would previously been missed by conventional 
sequencing. Rather than sequencing the entire genome or 
exome, clinical cancer gene test which include genes that 
show frequent alterations in cancer can save the amount of 
tissue, time and effort to perform sequencing. These panels 
use PCR capture-based NGS assay that allow deep targeted 
sequencing of genes of interest from limited formalin-
fixed, paraffin-embedded (FFPE) specimens [13]. Since 
incorporating NGS into routine oncologic practice requires 
accurate genomic profiling in a single assay, clinical cancer 
gene test may be appropriately used for clinical use.
In this study, we aimed to discover novel 
mechanisms of primary resistance to EGFR TKIs by using 
patient tumor samples from a large-scaled, prospective 
trial. We performed clinical cancer gene test of patient 
tissue samples which were obtained before treatment with 
EGFR TKIs in order to identify genetic alterations that 
confer primary resistance to EGFR TKIs.
RESULTS
Patient characteristics
The baseline characteristics of all patients are 
summarized in Table 1. The median age of all patients 
was 60 (range, 32-84) and there were 86 females (63.3%). 
The majority of patients (61%) were never-smokers and 
nearly all patients had adenocarcinoma histology (97.8%). 
At the time of their cancer diagnosis, 1 patient (0.7%) had 
stage IIIB disease, 119 (87.5%) had stage IV disease, 
and 16 (11.8%) had relapsed after surgical resection of 
lung cancer. EGFR mutations included exon 19 deletion 
(n=75), L858R mutation (n=65) and the rest included 
G719X, L861Q and others (n=6). Ten patients had two 
or more coexisting EGFR mutations (complex mutation).
Treatment outcome of EGFR TKI
The median follow-up duration was 14 months and 
101 (74.3%) patients received gefitinib as their first-line 
of treatment. As for best response, 87 patients (63.8%) 
showed partial response (PR), 33 patients (24.5%) showed 
SD and 6 patients (4.4%) showed PD (Table 2). Ten 
patients (7.3%) had not undergone response evaluation 
due to clinical disease progression, study withdrawal and 
follow-up loss. According to our prespecified definition of 
primary resistance to EGFR TKI, 20 patients showed PD 
as best response to gefitinib or PFS of less than 4 months. 
We classified them as non-responders to gefitinib. The 
median PFS was 9.1 months (95% confidence interval 
[CI] 7.15 – 11.05) for all patients, 13.8 months (95% CI, 
12.03 – 15.57) for responders, 1.7 months (95% CI, 0.67 
– 2.72) for non-responders (Figure 1A). The median OS 
for responders was 37.5 months (95% CI, 26.52 – 48.18), 
whereas it was 9.3 months (95% CI, 0.0-20.32) for non-
responders (Figure 1B). When OS was compared only 
among patients who received gefitinib for their first line 
therapy, the median OS was 37.5 months (95% CI, 24.98 – 
50.02) for responders and 4.5 months (95% CI, 0 – 16.19) 
for non-responders (Supplementary Figure S1).
Genomic landscape of responders and 
non-responders
The genomic landscape of 136 patients is depicted 
in Figure 2. A total of 543 somatic single-nucleotide 
variants (498 missense, 13 nonsense) and 32 frameshift 
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Table 1: Baseline characteristics of all patients (N=136)
Characteristic N %
Age (years)
 Median 60
 Range 32-84
Gender
 Male 50 36.7
 Female 86 63.3
Smoking history
 Never-smoker 83 61
 Ever smoker 53 49
Histologic diagnosis
 Adenocarcinoma 133 97.8
 Squamous 1 0.7
 Adenosquamous 2 1.5
Clinical stage
 IIIB 1 0.7
 IV 119 87.5
 Postoperative relapse 16 11.8
Type of EGFR mutation*
 Exon 19 deletion 75 51.4
 L858R 65 44.5
 Others* 6 4.1
* 10 patients had two or more coexsiting EGFR mutations
Table 2: Summary of EGFR TKI treatment outcome
Characteristic N %
Number of previous treatment
0 101 74.3
1 32 23.5
2 3 2.2
Best response
 Complete response 0 0
 Partial response 87 63.8
 Stable disease 33 24.5
 Progressive disease 6 4.4
 Not assessable 10 7.3
EGFR TKI
 Gefitinib 136 100
 Erlotinib 0 0
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Figure 1: Kaplan-Meier curve showing A. median progression-free survival and B. median overall survival among responders and 
non-responders to gefitinib.
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insertions/deletions, with a median of 3 mutations per 
sample. All patients harbored EGFR mutations (not 
depicted in Figure 2), and EGFR mutations included 
deletions in exon 19 (n=75), L858R (n=65), 1 missense 
mutation (Thr751Pro) in exon 19, 1 de novo T790M 
gatekeeper mutation in exon 20, 1 missense mutation 
(L861Q) in exon 19, 2 missense mutation (G873R, 
K860I) in exon 21, and 1 missense mutation (N700S) 
in exon 18.
The median number of mutations per sample in 
non-responders was 4, whereas the median number of 
mutations per sample in responders was 3. The number 
of mutations was significantly greater in non-responders 
compared to responders (13.6% vs. 10.6%, P = 0.009). 
There were 4 smokers who concurrently harbored 
6 to 9 mutations among non-responders whereas all 
responders had mutations range from 1 to 4. In non-
responders, all patients harbored TP53 mutations and 
the proportion of smokers was higher than in responders 
(50% vs. 37%, P = NS). Of note, KRAS mutations were 
identified in 3 patients among non-responders, which 
were previously not detected by conventional testing by 
direct sequencing method.
TP53 was most commonly mutated (47%) in all 
patients. Mutations in SMAD4 was also common (19%), 
as well as DDR2 (16%), PIK3CA (15%), STK11 (14%), 
and BRAF (7%). Recurrent mutations in AKT1, ALK, 
CTNNB1, ERBB2, ERBB4, FGFR1-3, MAP2K1, MET, 
NOTCH1, NRAS, and PTEN were also noted.
Mechanisms of primary resistance to EGFR TKI
Genomic mutations in the PI3K/Akt/mTOR pathway 
were commonly found in non-responders compared to 
responders (45% vs. 27%), although the difference was not 
significant. These mutations included missense mutations 
in AKT1, PIK3CA, STK11, nonsense mutations in PIK3CA, 
PTEN, and frameshift indels in PTEN. Patients with mutations 
in the PI3K/Akt/mTOR pathway had significantly shorter PFS 
and OS compared to those without (2.1 vs. 12.8 months, 
P=0.03, 15.7 vs. not reached, P < 0.001) (Figure 3A, 3B). 
FGFR 1-3 alterations were also more commonly found in 
non-responders compared to non-responders (20% vs. 8.3%, 
P = NS). All KRAS mutations were detected in non-responders 
(15% vs. 0%, P < 0.001), and TP53 mutations were detected 
in 100% of non-responders compared to 39% in responders 
(P < 0.001). There were no significant differences in alterations 
between the patients who showed upfront resistance (n=5) vs. 
patients with stable disease < 4 months (n=15).
DISCUSSION
Here, we described genomic alterations identified in 
patient tumors that showed primary resistance to gefitinib. 
We suggest that PI3K/Akt/mTOR pathway alterations may 
confer resistance to gefitinib.
Although EGFR TKI has undoubtedly revolutionized 
the treatment of EGFR-mutant lung cancer patients, but 
more investigation is necessary to elucidate mechanisms 
Figure 2: Landscape genomic profile of patients. Samples are grouped by response to gefitinib.
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Figure 3: Kaplan-Meier curve showing A. median progression-free survival and B. median overall survival among patients with 
or without PI3K/Akt/mTOR pathway alterations.
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of primary resistance to EGFR TKI. Previous studies have 
assessed mechanisms of primary resistance to EGFR TKIs: 
alterations in EGFR-downstream genes, EGFR T790M 
mutation, KRAS mutation, cMET amplification and HGF 
overexpression [19-22]. However, most studies did not 
comprehensively examine the genomic alterations in 
association with treatment outcomes to EGFR TKI.
In our study, patients with pathway alterations in 
PIK3CA/Akt/mTOR pathway had significantly shorter 
PFS to EGFR TKI compared to those without. Genetic 
alterations in the PIK3CA/Akt/mTOR pathway may impact 
the response to EGFR TKI. This finding is consistent 
with the previous study that reported that mutations in 
EGFR-downstream genes such as PIK3CA, AKT, PTEN 
and STK11 were associated with de novo resistance to 
EGFR TKI [8]. PIK3CA mutations were identified in 
7% of our patients, and somatic missense mutations in 
helical or kinase domains of catalytic subunit encoded 
by the PIK3CA gene, which is known to increase the 
kinase activity of PIK3CA contributing to cellular 
transformation, were found in 2 out of 5 non-responder 
patients. We assume that activating PIK3CA mutations 
may have impaired response to EGFR TKI. Nine AKT 
mutations (5%) were identified in our patients and all 
mutations were located in pleckstrin homology domain. Of 
note, AKT1 E17K mutation, previously known to activate 
PI3K pathway, was found in 1 non-responder which 
could explain the non-response to gefitinib [23]. PTEN 
is a tumor suppressor gene which negatively regulates 
the PI3K/Akt/mTOR pathway, and loss of PTEN was 
previously identified as a poor prognostic marker [24]. 
While 1 frameshift deletion (p.Glu242fs) has been noted 
in a non-responder, its functional impact is not yet known. 
Mutations in STK11 were commonly identified (14%) and 
inactivation of STK11 has been known to promote lung 
tumorigenesis and associated with worse survival outcome 
[25, 26]. Pathogenic STK11 mutations (p.Phe354Leu) 
were recurrently identified in 3 non-responders whereas 
pathogenic mutations were not seen in responders. In 
patients with PI3K/Akt/mTOR pathway alterations, 
combination of PI3K inhibitor with gefitinib may be 
attempted to as a new therapeutic option.
Apart from PIK3CA/Akt/mTOR pathway alterations, 
KRAS mutations were identified exclusively in non-
responders. KRAS mutations are known predictors of 
resistance to EGFR TKI [21], and interestingly, these 
mutations were previously not found with conventional 
sequencing. Possible reasons for the discordant results 
are low sensitivity of detection method and intratu-
moral heterogeneity. Genomic alterations with low allele 
frequencies lead to false-negative results on conventional 
sequencing and subclonal mutations may be heterogeneous 
according to biopsy sites [27, 28].
TP53 was the most commonly altered gene in our 
study and this is consistent with findings from previous 
studies [29]. Of note, all non-responders had TP53 
mutations (frameshift deletion and missense mutations). 
Interestingly, it has been reported that TP53 may enhance 
sensitivity to EGFR inhibitor, and loss of TP53 may lead 
to resistance to EGFR inhibitor [30]. Four pathogenic 
mutations were identified among non-responders, and 
they may have led to functional loss of TP53, resulting in 
primary resistance to gefitinib.
Six uncommon EGFR mutations identified in 
our study were missense mutations in exon 18 (F712S, 
G721A) and 19 (A743S, P733L, L747F, N756D). Their 
oncogenicity and sensitivity to EGFR TKI have not been 
fully elucidated. Wu et al. observed an objective response 
rate of 48.4% and a median PFS of 5.0 months in patients 
with uncommon EGFR mutations [31]. In our study, two 
uncommon EGFR mutations were identified among non-
responders and four were identified among responders. 
Prospective trials which examine the efficacy of EGFR 
inhibitors in patients with uncommon EGFR mutations are 
necessary.
Our study has a few limitations. The selected genes 
in this study may only explain a portion of mechanisms 
of resistance. Other genetic or epigenetic alterations 
that are not covered in the gene test may be missed out 
even if they promote resistance to EGFR TKI. However, 
most tumor samples were acquired from small biopsy 
samples and thus there were not enough tissue available 
for a more comprehensive sequencing. In addition, the 
number of patients analyzed was relatively small and 35 
(25.7%) patients did not receive gefitinib as their first line 
of therapy, so data must be interpreted cautiously. Lastly, 
functional effects of resistant alterations were not assessed 
in vitro.
In conclusion, we note that more comprehensive 
genomic characterization of the tumor reveals alterations 
that may confer resistance to EGFR TKI in EGFR-mutant 
lung adenocarcinoma patients. This study highlights 
previously unappreciated genetic alterations, enabling 
further refinement in sub-classification for the improved 
personalization of lung cancer treatment.
MATERIALS AND METHODS
Study populations
A total of 152 patients with NSCLC harboring 
activating EGFR mutations were enrolled in a prospective 
trial of gefitinib between 2012 and 2015 at institutions 
in Korean Lung Cancer Consortium. Activating EGFR 
mutations were defined as mutations known to be 
associated with EGFR TKI sensitivity, including exon 19 
deletion and L858R [14]. Patients with available archival 
tissue and those with measurable lesions at baseline were 
enrolled. This study was approved by the Institutional 
Review Board of Severance Hospital and the ethics 
committee. All patients provided written informed consent 
for study participation and genetic analysis.
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Data collection
Medical records and radiologic images of all 
patients were reviewed to evaluate demographic and 
clinicopathologic parameters, tumor response and 
progression-free survival (PFS) and overall survival (OS) 
using a predesigned data collection format. PFS was 
measured from the first day of treatment with EGFR TKI 
to tumor progression or death. OS was measured from 
the first date of treatment with EGFR TKI until the date 
of death. Patients were censored on December 7, 2015 if 
alive and progression-free. Never-smokers were defined 
as those with a lifetime smoking-dose less than 100 
cigarettes.
Tumor assessment
Response to gefitinib was assessed by a computed 
tomography scan performed at 4 weeks and then every 
8 weeks thereafter in accordance with the Response 
Evaluation Criteria in Solid Tumors (RECIST) version 
1.1 [15]. Primary resistance to EGFR TKIs was defined 
as followings: (1) the best response to EGFR TKI is 
progressive disease (PD) and (2) PFS to EGFR TKI 
is less than 4 months with stable disease (SD) as best 
response [8, 16].
Genetic analysis
Tumor samples from 136 patients were available 
for genetic alterations. DNA was extracted from FFPE 
tumor samples using the QIAamp FFPE tissue kit 
(Qiagen, Antwerp, Belgium). The DNA obtained was 
quantified using the Qubit® fluorometer in combination 
with the Qubit dsDNA HS assay kit (Life Technologies, 
Gent, Belgium). For library construction, 10ng of DNA 
was amplified using the Colon and Lung Cancer panel 
(Ampliseq, Life Technologies). An amplicon library was 
generated for sequencing 1825 hotspot mutations in 22 
genes including AKT1 (NM_05163), ALK (NM_004304), 
BRAF (NM_004333), CTNNB1 (NM_001904), DDR2 
(NM_001014796), EGFR (NM_005228), ERBB2 
(NM_004448), ERBB4 (NM_005235), FBXW7 
(NM_033632), FGFR1 (NM_023110), FGFR2 
(NM_022970), FGFR3 (NM_000142), KRAS (NM_033360), 
MAP2K1 (NM_002755), MET (NM_001127500), 
NOTCH1 (NM_017617), NRAS (NM_002524), 
PIK3CA (NM_006218), PTEN (NM_000314), SMAD4 
(NM_005359), STK11 (NM_000455), TP53 (NM_000546). 
The amplicons were then digested, barcoded and amplified 
using the Ion Ampliseq™ Library kit 2.0 and Ion Xpress™ 
barcode adapters kit (Life technologies) according to the 
manufacturer’s instructions. The library was quantified 
using the Qubit1 fluorometer and the Qubit1 dsDNA HS 
assay kit (Life technologies). 8pM of each library was 
multiplexed and clonally amplified on Ion sphere™ particles 
(ISP) by emulsion PCR performed on the Ion One Touch 2 
instrument with the Ion PGM™ template OT2 200 kit (Life 
technologies) according to the manufacturer’s instructions. 
Quality control was performed using the Ion Sphere™ 
Quality Control kit (Life Technologies) to ensure that 10–
30% of template positive ISP were generated in the emulsion 
PCR. Finally, the template ISP were enriched, loaded on 
an Ion 316™ or on an Ion 318™ chip and sequenced on a 
PGM™ sequencer with the Ion PGM™ sequencing 200 kit 
v2 according to the manufacturer’s instructions.
Data analysis
The raw data were analyzed using the torrent 
suite software v3.6.2 (Life technologies). The coverage 
analysis was performed using the coverage analysis plug-
in v3.6. Cases for which the number of mapped reads was 
<100000 and/or the average base coverage was <500x were 
considered as non-informative. Mutations were detected 
using the Variant Caller plug-in v3.6 with low stringency 
settings (Life Technologies). In the variant list obtained, 
each mutation was verified in the Integrative genome viewer 
(IGV) from the Broad Institute (http://www.broadinstitute.
org/igv/). Only mutations reported in the COSMIC (Sanger 
Institute Catalogue of Somatic Mutations in Cancer) 
database (http://www.sanger.ac.uk/cosmic) were taken into 
account and silent or intronic mutations were not reported. 
Locis were further analyzed for functional prediction 
of amino acid changes using two different prediction 
algorithms (Provean and SIFT) [17, 18].
Statistical analysis
OS and PFS were estimated using the Kaplan–
Meier method. Differences between groups were 
compared by the log-rank test. Two-sided P-values < 
0.05 were considered significant. All analyses were 
carried out using SPSS 20.0 (IBM SPSS Statistics, IBM 
Corp., Somers, NY).
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